TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01775189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALO-02 weight-matched placebo
Description: crushed sugar spheres (powder) x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crushed ALO-02 30 mg/3.6 mg
Description: crushed ALO-02 30 mg/3.6 mg capsule x 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxycodone weight-matched placebo
Description: crushed lactose tablets (powder) x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crushed oxycodone IR 30 mg
Description: Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
Study: NCT03638414

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePainQ questionnaire
Description: This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
Study: NCT04005014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myopia prediction algorithm
Description: Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
Study: NCT01028924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teduglutide
Description: subcutaneous (SC), single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teduglutide
Description: subcutaneous (SC), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: subcutaneous (SC), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: subcutaneous (SC), single dose
Study: NCT04131738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib may be taken without regard to food. It should be taken at the same time every day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib may be taken without regard to food. It should be taken at the same time every day.
Study: NCT02329535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: vaginal caps 400 mg daily up to 36 weeks of gestation
Study: NCT00637767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183
Study: NCT03218124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remifentanil Effect site concentration
Description: After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method).
Study: NCT03482258

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
Study: NCT03242200

Intervention type: OTHER
Group type: OTHER
Intervention: Mobile Health App
Description: Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
Study: NCT01613313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
Study: NCT03301571

Intervention type: OTHER
Group type: OTHER
Intervention: Change in preload and afterload
Description: Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated

Intervention type: OTHER
Group type: OTHER
Intervention: Inspired oxygen
Description: Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively

Intervention type: OTHER
Group type: OTHER
Intervention: Pacemaker mode
Description: Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
Study: NCT06290908

Intervention type: PROCEDURE
Intervention: RPE-P/TLIF
Description: patients with lumbar spinal stenosis and instability who met the inclusion and exclusion criteria were treated with RPE-P/TLIF
Study: NCT04207489

Intervention type: PROCEDURE
Intervention: endoscopic submucosal injection of indocyanine green before laparoscopic radical operation of colorectal cancer
Description: Indocyanine green was injected under endoscope within 24 hours before operation. Four points were evenlyinjected in four quadrants at the edge of the tumor. The patients with obstruction were injected at two points on the anal side of the tumor. The diluted concentration of indocyanine green was 0.625mg/ml or 1.25mg/ml. The injection method was direct submucosal injection and sandwich method. According to the imaging effect, it can be divided into local imaging and lymphatic drainage imaging. Tumor body: 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation. Lymph drainage area imaging 0, no imaging; 1, full imaging; 2, diffuse imaging, overflow, interference with other areas of observation.
Study: NCT01484327

Intervention type: DRUG
Intervention: Carvedilol
Description: Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
Study: NCT00843635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Given orally
Study: NCT03785249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered as an intravenous infusion once per week or once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally once a day in a continuous regimen
Study: NCT03398642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: French Lifestyle Redesign
Description: Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
Study: NCT03341364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT-based group therapy
Description: 6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT individual treatment
Description: 3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
Study: NCT01368172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Guidelines
Description: Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
Study: NCT05927675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The exercise intervention program consisted of two distinct periods. During period 1, subjects participated in a moderate to vigorous intensity exercise program for 40 minutes a day, 4 days a week. The exercise program was conducted in Tabata format targeting 70% of the maximum heart rate. Recovery was then induced for 1 minute and 30 seconds, allowing the heart rate to return to resting levels. The exercise routine primarily consisted of full-body exercises, functional training, and power exercises.~During period 2, a low-intensity static exercise program was implemented. Similar to period 1, the subjects exercised for 40 minutes a day, 4 days a week. The exercise program included static exercises. The maximum heart rate was maintained below 50%. The detailed exercise program consisted of stretching movements and balance movements.
Study: NCT02797665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: prednisone 0.6mg/kg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: prednisone 0.6mg/kg/d
Study: NCT03225625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal
Description: BMSC provided by paraspinal injection, intravenous and intranasal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal
Description: BMSC provided by paraspinal injection, intravenous and intranasal
Study: NCT01777256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 100 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 200 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
Study: NCT00843635

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT02506283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zamar Therapy CT clinic
Description: Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Zamar Therapy CT clinic
Description: Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
Study: NCT00476775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: after school ethnic dance program - ballet folklorica
Study: NCT03225625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal
Description: BMSC provided by paraspinal injection, intravenous and intranasal
Study: NCT00476775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally-tailored, home-based screen time reduction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: culturally-tailored health and nutrition education
Study: NCT03244644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBX2660
Description: RBX2660 is a rectally administered microbiota suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline solution administered rectally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open label RBX2660 (only for confirmed CDI recurrence)
Description: RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open label RBX2660 (only for confirmed CDI recurrence)
Description: RBX2660 administered as a second treatment after confirmed CDI recurrence following the initial dose of placebo or RBX2660
Study: NCT01777256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 400 mg
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
Study: NCT04414345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNM-Au8
Description: Drug: CNM-Au8~Administration: Oral~Dosage: 30 mg or 60 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Drug: Matching Placebo~Administration: Oral~Dosage: 2 bottles daily
Study: NCT03390426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: An ultrasound guided injection of mepivacaine superomedially to the femoral artery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perifemoral Injection of Local Anesthetic
Description: An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Perifemoral Injection of Local Anesthetic
Description: An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
Study: NCT00685776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anacetrapib
Description: Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Participants will receive one placebo tablet once daily for 76 weeks.
Study: NCT01777256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.
Study: NCT00596076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back School
Description: All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month.
Study: NCT00323466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMRT versus conventional radiotherapy
Description: Comparing MRT versus conventional radiotherapy
Study: NCT01906515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive hemoglobin monitoring
Description: Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
Study: NCT03450044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cells
Description: Adoptive transfer of autologous DCs
Study: NCT04292288

Intervention type: DIAGNOSTIC_TEST
Intervention: Biochemical observational
Description: no intervention - observational
Study: NCT02985216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119
Description: YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica
Description: Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
Study: NCT03483363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical irrigation with gentamicin (80mg diluted in 1L 0.9% normal saline)
Description: Fractures will be irrigated with the topical antibiotic gentamicin (80mg diluted in 1L 0.9% normal saline) prior to closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical irrigation with sterile normal saline (NS)
Description: Fractures will be irrigated with sterile normal saline prior to closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous (IV) prophylactic antibiotic
Description: All arms with receive standard parenteral (IV) prophylactic antibiotic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous (IV) prophylactic antibiotic
Description: All arms with receive standard parenteral (IV) prophylactic antibiotic.
Study: NCT01797237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFNA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PFNA
Study: NCT01777256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.
Study: NCT03922425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community mental health team
Description: CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
Study: NCT01797237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterTAN

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterTAN
Study: NCT04185623

Intervention type: PROCEDURE
Intervention: denudation time lag
Description: The time between ovum pickup and denudation of oocyte

Intervention type: PROCEDURE
Intervention: denudation time lag
Description: The time between ovum pickup and denudation of oocyte
Study: NCT03225625

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal EX
Description: BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraspinal VR
Description: BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
Study: NCT01556594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon 1 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon 2 mg
Study: NCT00658515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (RO4607381)
Description: 600mg po daily
Study: NCT00901446

Intervention type: DEVICE
Intervention: Intravascular ultrasound and spectroscopy
Description: Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
Study: NCT01169142

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 50,000 units of Vitamin D3 weekly

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 50,000 units weekly
Study: NCT04049123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT01355341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HERBMED PLUS
Description: 500 mg Twice day for 6 month with lunch and dinner.
Study: NCT00296894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg sc every other week)
Description: Adalimumab (40 mg sc every other week)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00658515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evidence-based medical care for Acute Coronary Syndrome
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evidence-based medical care for Acute Coronary Syndrome
Description: As prescribed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily
Study: NCT03408535

Intervention type: OTHER
Group type: OTHER
Intervention: Eriksholm Guide to Better Hearing
Description: Online rehabilitation program.